Trastuzumab-related subclinical cardiotoxicity in patients with early stage HER2-positive breast cancer: A retrospective single-center cohort study.

被引：0
|
作者：
Aseyev, Olexiy
Rushton-Marovac, Moira
Crawley, Freya L.
Johnson, Christopher
Dent, Susan Faye
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.10123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10123
引用
收藏
页数：5
相关论文
共 50 条
  • [31] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
    Ratti, Riccardo
    Coccorullo, Zaira
    Guarneri, Domenico
    Colloca, Giuseppe
    Venturino, Antonella
    Addamo, Gianfranco
    Campora, Elisabetta
    ANNALS OF ONCOLOGY, 2009, 20
  • [32] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Colloca, G.
    Addamo, G.
    Venturino, A.
    Campora, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 45 - 45
  • [33] Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, Greg L.
    Keam, Susan J.
    BIODRUGS, 2006, 20 (04) : 259 - 262
  • [34] Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients
    Toukabri, Imen
    Ben Said, Azza
    Hamdi, Adel
    Aloulou, Aziza
    Ben Ayed, Wiem
    Cherif, Ines
    Limayem, Imen
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 613 - 618
  • [35] Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
    Bonardeaux, Orianne de la Brassinne
    Born, Benjamin
    Moonen, Marie
    Lancellotti, Patrizio
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [36] Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (07): : 851 - +
  • [37] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    BioDrugs, 2006, 20 : 259 - 262
  • [38] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [39] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [40] Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
    Down, Sue K.
    Lucas, Olivia
    Benson, John R.
    Wishart, Gordon C.
    ONCOLOGY LETTERS, 2014, 8 (06) : 2757 - 2761
12345